Table 3 The CECT features of included lesions
Imaging features | cHCC-CCAa (n = 45) | HCC (n = 90) | p value# |
|---|---|---|---|
CT scan | |||
 Size (cm) | 5.5 ± 3.6 | 5.3 ± 3.4 | 0.719 |
 Number of tumors (single) | 33 (73.3) | 82 (80.0) | 0.511 |
 Cirrhosis | 20 (44.4) | 62 (68.9) | 0.009 |
CECT | |||
LI-RADS major features | |||
 Nonrim APHE volume (< 50%) | 26 (57.8) | 11 (12.2) | < 0.001 |
 Rim APHE | 17 (37.8) | 5 (5.6) | < 0.001 |
 Nonperipheral washout volume (< 50%) | 22 (48.9) | 18 (20.0) | < 0.001 |
 Peripheral washout | 22 (48.9) | 8 (8.9) | < 0.001 |
 Enhancing capsule | 28 (62.2) | 52 (57.8) | 0.621 |
 Tumor in vein | 1 (2.2) | 8 (9.0) | 0.169 |
LI-RADS category |  |  | < 0.001 |
 LR-3 | 1 (2.2) | 2 (2.2) |  |
 LR-4 | 8 (17.8) | 8 (8.9) |  |
 LR-5 | 12 (26.7) | 61 (67.8) |  |
 LR-M | 23 (51.1) | 11(12.2) |  |
 LR-TIV | 1 (2.2) | 8 (8.9) |  |
LI-RADS ancillary features | |||
 Corona enhancement | 11 (24.4) | 21 (23.3) | 0.889 |
 Nonenhancing capsule | 4 (8.9) | 17 (18.9) | 0.132 |
 Nodule-in-nodule architecture | 9 (20.0) | 23 (25.6) | 0.526 |
 Mosaic architecture | 11 (24.4) | 30 (33.3) | 0.326 |
 Blood products in mass | 2 (4.4) | 5 (5.6) | 1.000 |
 Fat in mass, more than adjacent liver | 0 (0.0) | 1 (1.1) | 1.000 |
 Delayed central enhancement | 2 (4.4) | 7 (7.8) | 0.464 |
 Internal artery | 14 (31.1) | 35 (38.9) | 0.449 |
 Necrosis or severe ischemia | 18 (40.0) | 48 (53.3) | 0.201 |
 Infiltrative appearance | 20 (44.4) | 38 (42.2) | 0.855 |
Other features | |||
 Tumor capsule integrity (incomplete) | 27 (60.0) | 36 (40.0) | 0.044 |
 Tumor margin (smooth) |  |  | 0.855 |
 Tumor growth subtype |  |  | < 0.001 |
  Type 1: single nodular type | 23 (51.1) | 62 (68.9) |  |
  Type 2: single nodule with extranodular growth | 12 (26.7) | 26 (28.9) |  |
  Type 3: multiple confluent nodules | 10 (22.2) | 2 (2.2) |  |
 Lesion with LR-M featuresb | 24 (53.3) | 11 (12.2) | < 0.001 |